期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

抗肿瘤药的进展与临床评价——肿瘤治疗合理用药专家圆桌会议纪要

暂未订购
导出
摘要 问讯湖边春色,万物绿染,重来又是一年。用药评点再续,小雪无痕,明日风回无限。本刊编辑部2008年于11月20日在京召开全国肿瘤治疗合理用药专家圆桌会议,来自天津、山西、山东、陕西和北京的临床医学、药学专家百余人汇集一堂,回顾历程,评点用药,瞻望未来,大会相继听取了朱军、冯威健、何作祥教授的报告,并与国外学者在天然药物的研发和应用上进行交流。肿瘤药物化疗已成为当前肿瘤治疗中最为活跃的研究领域,成为肿瘤综合治疗中最为重要的手段。提高患者的生活质量,延长生存期,既寄托于临床治疗药物进展,也期盼于多学科综合协作,借以造福于社会,受益于公众。
作者 程迎秋 张石革
机构地区 中国药房杂志社北京办事处 北京积水潭医院
出处 《中国医院用药评价与分析》 2009年第1期1-3,共3页 Evaluation and Analysis of Drug-use in Hospitals of China
关键词 合理用药 肿瘤治疗 圆桌会议 临床评价 专家 抗肿瘤药 肿瘤综合治疗 临床医学
分类号 R969.3 [医药卫生—药理学] R730.5 [医药卫生—肿瘤]
  • 相关文献

参考文献12

  • 1Kumar A, Wakelee H. Second- and third-line treatments in non-small cell lung cancer [ J ]. Curr Treat Options Oncol, 2006,7(1):37.
  • 2Wedam SB, Low JA, Yang SX, et al. Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer[J]. J Clin Oncol, 2006, 24(5) :769.
  • 3Folkman J. Tumor angiogenesis: therapeutic implications[J]. N Engl J Med, 1971,285(21 ) : 1 182.
  • 4Leung DW, Cachianes G, Kuang W J, et al. Vascular endothelial growth factor is a secreted angiogenic mitogen[J]. Science, 1989,246 (4 935) : 1 306.
  • 5Bono P,Teerenhovi L,Joensuu H. Elevated serum endostatin is associated with poor outcome in patients with non-Hodgkin lymphoma[J] . Cancer, 2003,97(11 ) :2 767.
  • 6Folkman J. Tumor angiogenesis : therapeutic implications [ J ]. New Engl J Med ,1971,285( 21) :1 182.
  • 7Ganjoo KN, Moore AM, Orazi A, et al. The importance of angiogenesis markers in the outcome of patients with diffuse large B cell lymphoma: a retrospective study of 97 patients [J] . J Cancer Res Clin Oncol,2008,134(3) :381.
  • 8Salven P, Orpana A, Teerenhovi L, et al. Simultaneous elevation in the serum concentrations of the angiogenic growth factors VEGF and bFGF is an independent predictor of poor prognosis in non-Hodgkin lymphoma: a single-institution study of 200 patients[J]. Blood,2000,96(12):3 712.
  • 9Ganjoo KN, An CS, Robertson MJ, et al. Rituximab, bevacizumab and CHOP (RA-CHOP) in untreated diffuse large B-cell lymphoma : safety, biomarker and pharmacokinetic analysis [ J ]. Leuk Lymphoma, 2006,47 ( 6 ) : 998.
  • 10Bertolini F, Fusetti L, Mancuso P, et al. Endostatin, an antiangiogenic drug, induces tumor stabilization after chemotherapy or anti-CD20 therapy in a NOD/SCID mouse model of human high-grade non-Hodgkin lymphoma [ J]. Blood, 2000,96 ( 1 ) : 282.

二级参考文献20

  • 1Dredge K, Horsfall R. Robinson SP. et al. Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro.Microvasc Res, 2005, 69(1-2):56-63.
  • 2Geitz H, Handt S. Zwingenberger K,et al. Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade. Immunopharmacology, 1996, 31(2 3):213-221
  • 3Gupta D. Treon SP. Hidehima T, et al. Adherence of muhiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion:therapeutic applications.Leukemia, 2001, 15(12)41950-1961.
  • 4Richardson P. Schlossman R. Anderson K. al,Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed muhiple myeloma, Blood.2002, 100(9):3063-3067.
  • 5Nicholas M, Constantine S, Mitsiades, et al. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood, 2002, 99(12):4525-4530.
  • 6Chauhan D, Li G, Hideshima T, et al. JNK-dependent release of mitochondrial protein, Smac, during apoptosis in muhiple myeloma(MM) cells. J Biol Chem, 2003, 278(20):17593-17596.
  • 7Davies FE, Raje N, Hideshima T, et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicityin multiple myeloma. Blood, 2001, 98(1):210-216.
  • 8Martin J, Andrea P, Ann-Marl F, et al. Lenalidomide Selectively Inhibits In Vitro Growth of the Malignant Clone in Myelodysplastic Syndrome (MDS) Patients with 5q Deletion. Blood, 9005, 106:960a.
  • 9Hideshima T, Chauhan D, Shima Y, et al. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood, 2000. 96(9) :2943-2950.
  • 10List AF. Kurtin S, Roe DJ,et al. Efficacy of Lenalidomide in Myelodysplastic Syndromes. N Engl J Med, 2005. 352 (6):549-557.

共引文献6

中国医院用药评价与分析
2009年 第1期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部